ArticleCureus2025
A Rare Type of Myeloma: A Case of Monoclonal IgD-Lambda.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An immunoglobulin D-multiple myeloma (IgD-MM) case represents a rare subtype of MM that is often observed in male patients under 65 years of age with an advanced stage at the time of diagnosis. It exhibits an aggressive course and is associated with a short survival period. In IgD-MM, an increase in lambda light chain proteins is expected. Given that IgD and IgE heavy chains are not routinely assessed in standard serum and serum immunofixation electrophoresis (IFE) analyses in MM patients, such cases may be misclassified and monitored as light chain myeloma. Therefore, distinguishing IgD or IgE myeloma from light chain myeloma represents a critical differential diagnosis. This case highlights the necessity of including IgD and IgE in diagnostic evaluations to prevent misclassification as light chain myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.